Indivior Pharmaceuticals, Inc. Net Income 2022–2025
Indivior Pharmaceuticals, Inc. reported $210.00M of net income for fiscal 2025. That was 537.5% higher than fiscal 2024. Compared with fiscal 2022, the change was +496.2%.
| Fiscal year | Net Income | Net margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $210.00M | 16.9% | +537.5% |
| FY 2024 | $-48.00M | -4.0% | -2500.0% |
| FY 2023 | $2.00M | 0.2% | +103.8% |
| FY 2022 | $-53.00M | -5.9% | — |
Source: Indivior Pharmaceuticals, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open INDV 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Indivior Pharmaceuticals, Inc. reported $210.00M of net income for fiscal 2025. That was 537.5% higher than fiscal 2024. Compared with fiscal 2022, the change was +496.2%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Indivior Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeIndivior Pharmaceuticals, Inc. — frequently asked questions
What is Indivior Pharmaceuticals, Inc.'s net income?
Indivior Pharmaceuticals, Inc. (INDV) reported net income of $210.00M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Indivior Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.